Volume | 13,242 |
|
|||||
News | - | ||||||
Day High | 0.33 | Low High |
|||||
Day Low | 0.321 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Coeptis Therapeutics Holdings Inc | COEP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.321 | 0.321 | 0.33 | 0.327 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
21 | 13,242 | $ 0.3213104 | $ 4,255 | - | 0.2851 - 2.1899 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:02:24 | 100 | $ 0.33 | USD |
Coeptis Therapeutics Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
407.59M | 34.11M | - | 0 | -21.27M | -0.62 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Coeptis Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COEP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.3699 | 0.3799 | 0.321 | 0.3362408 | 105,504 | -0.0399 | -10.79% |
1 Month | 0.291 | 0.48 | 0.2851 | 0.3687024 | 297,416 | 0.039 | 13.40% |
3 Months | 0.59 | 0.679 | 0.2851 | 0.4392127 | 272,242 | -0.26 | -44.07% |
6 Months | 1.34 | 1.38 | 0.2851 | 0.608594 | 198,079 | -1.01 | -75.37% |
1 Year | 1.27 | 2.1899 | 0.2851 | 0.9783561 | 162,838 | -0.94 | -74.02% |
3 Years | 8.20 | 8.7551 | 0.2851 | 1.29 | 185,439 | -7.87 | -95.98% |
5 Years | 8.20 | 8.7551 | 0.2851 | 1.29 | 185,439 | -7.87 | -95.98% |
Coeptis Therapeutics Description
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania. |